These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
3. Head-to-Head Comparison of SSTR Antagonist [ Viswanathan R; Ballal S; Yadav MP; Roesch F; Sheokand P; Satapathy S; Tripathi M; Agarwal S; Moon ES; Bal C Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543061 [TBL] [Abstract][Full Text] [Related]
4. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479 [TBL] [Abstract][Full Text] [Related]
5. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Berzaczy D; Giraudo C; Haug AR; Raderer M; Senn D; Karanikas G; Weber M; Mayerhoefer ME Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844 [TBL] [Abstract][Full Text] [Related]
7. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors. Ansquer C; Touchefeu Y; Faivre-Chauvet A; Leux C; Le Bras M; Régenet N; Fleury V; Maucherat B; Senellart H; Guyetant S; Carlier T; Scotet-Cérato E; Rauscher A; Frampas E; Kraeber-Bodéré F Clin Nucl Med; 2021 Mar; 46(3):181-186. PubMed ID: 33315677 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? Sharma P; Arora S; Mukherjee A; Pal S; Sahni P; Garg P; Khadgawat R; Thulkar S; Bal C; Kumar R Clin Nucl Med; 2014 Jan; 39(1):37-43. PubMed ID: 24152621 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma. Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors. Sharma A; Das CJ; Makharia GK; Arora G; Kumar R Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875 [TBL] [Abstract][Full Text] [Related]
13. Comparison of diagnostic efficacy of Zhang B; He Q; Long Y; Zhang Y; Wang X; Chen Z; Liu J; Zhang X Front Endocrinol (Lausanne); 2022; 13():962800. PubMed ID: 36213295 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors. Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577 [TBL] [Abstract][Full Text] [Related]
15. Paget's Disease Mimicking Bone Metastasis in a Patient with Neuroendocrine Tumor on Gezer NS; Balcı A; Özdoğan Ö; Özaksoy D J Belg Soc Radiol; 2016 Jul; 100(1):66. PubMed ID: 30151468 [TBL] [Abstract][Full Text] [Related]
16. [68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? Tabacchi E; Fortunati E; Argalia G; Zanoni L; Calabrò D; Telo S; Campana D; Lamberti G; Ricci C; Casadei R; Fanti S; Ambrosini V Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884602 [TBL] [Abstract][Full Text] [Related]
17. Role of Ga-68 DOTANOC Positron Emission Tomography/ Computed Tomography Scan in Clinical Management of Patients with Neuroendocrine Tumors and its Correlation with Conventional Imaging- Experience in a Tertiary Care Center in India. Singh D; Arya A; Agarwal A; Agarwal G; Ravina M; Gambhir S Indian J Nucl Med; 2022; 37(1):29-36. PubMed ID: 35478677 [TBL] [Abstract][Full Text] [Related]
18. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. Madrzak D; Mikołajczak R; Kamiński G Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886 [TBL] [Abstract][Full Text] [Related]
19. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Mayerhoefer ME; Ba-Ssalamah A; Weber M; Mitterhauser M; Eidherr H; Wadsak W; Raderer M; Trattnig S; Herneth A; Karanikas G Eur Radiol; 2013 Jul; 23(7):1978-85. PubMed ID: 23471430 [TBL] [Abstract][Full Text] [Related]